Who we are
Oncolix, Inc. (Oncolix) is a clinical-stage bio-pharmaceutical company
based in Houston, Texas. We are developing Prolanta™, a targeted
therapeutic protein for the treatment of ovarian, breast and other
cancers. The Company has a US FDA-cleared IND to commence human testing
of Prolanta™ in our first indication, the treatment of ovarian cancer.
This clinical trial is expected to begin in late 2015. Prolanta™ is a
prolactin receptor antagonist that has demonstrated significant efficacy
in xenograft models through a unique mechanism of action, autophagy (see
Our Science). In addition to ovarian cancer, there is strong preclinical
evidence Prolanta™ will be effective in breast, prostate and other
The FDA has also approved the designation of
Prolanta™ as an
Orphan Drug for the treatment of ovarian cancer, which may allow an
accelerated regulatory approval by the FDA, reduced filing fees, federal
tax credits and marketing exclusivity.